Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying DB-1303BNT323, a biological drug, in a Phase 12a trial to evaluate its safety and tolerability in adults with advanced or metastatic malignant solid tumors that express HER2. The trial focuses on patients whose tumors are refractory to standard treatments or have no available standard options. This first-in-human study includes both a dose-escalation phase to find the maximum tolerated dose and a dose-expansion phase to further assess safety and explore efficacy in selected tumors. Participants receive DB-1303BNT323 intravenously once every three weeks at various dose levels, including a randomized comparison of doses during some expansion cohorts. Additional treatments may include ritonavir or itraconazole to assess drug interactions, and in some cases, DB-1303BNT323 is combined with Pertuzumab. The study is open-label and multicenter, with dosing continuing according to the protocols schedule. During the trial, participants undergo regular assessments including safety monitoring for adverse events, dose-limiting toxicities, and serious adverse events up to about one year post-treatment. Researchers measure tumor response using RECIST 1.1 criteria and evaluate pharmacokinetics and pharmacodynamics. Organ function, heart performance, and life expectancy are also monitored throughout this period. The estimated study completion is in October 2027.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.
Actively Recruiting
The trial investigates the effectiveness and safety of two dosing schedules of pegozafermin compared to a placebo in adults with metabolic dysfunction-associated steatohepatitis MASH who have liver fibrosis stages F2 or F3. This phase 3 study focuses on people aged 18 to 80 years and aims to better understand treatment options for this liver condition. Participants will be randomly assigned to receive one of two pegozafermin regimens or a matching placebo. Both pegozafermin and placebo are given by subcutaneous injection. The study includes a treatment period lasting up to 52 weeks, during which the effects of these regimens on liver fibrosis and steatohepatitis will be assessed. Throughout the study, participants will undergo various evaluations including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and monitoring for disease progression for up to five years. Researchers will track improvements in liver fibrosis, resolution of steatohepatitis, changes in liver enzyme levels, and fibrosis scores to assess the impact of the treatments.
Actively Recruiting
Researchers are evaluating the efficacy and safety of pegozafermin in adults aged 18 to 75 years who have biopsy-confirmed and clinically confirmed compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis MASH. This phase 3 study aims to compare pegozafermin against a matched placebo to better understand its effects on liver fibrosis and disease progression in this population. Participants will receive either pegozafermin or a placebo through subcutaneous injections. The study is randomized and quadruple-blinded, ensuring neither participants nor researchers know which treatment is given. Treatment effects will be observed over a period of up to 5 years, with primary outcomes measured at 24 months, including fibrosis regression and time to disease progression based on specified clinical events. Throughout the study, participants will undergo regular assessments, including liver function tests like ALT and AST, enhanced liver fibrosis scores, FibroScan elastography, and evaluations for portal hypertension and other liver-related complications. Safety monitoring will track adverse events during the treatment and follow-up period. The trial spans several years, allowing long-term observation of treatment outcomes and participant health.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of ponsegromab combined with systemic chemotherapy compared to chemotherapy plus placebo for adults with metastatic pancreatic ductal adenocarcinoma mPDAC who have cachexia, a condition causing significant weight loss and fatigue. This Phase 2b3, randomized, double-blind study involves adult participants who have completed initial chemotherapy cycles and aims to improve treatment outcomes for this challenging condition. Participants will receive either one of two doses of ponsegromab or a placebo alongside first-line chemotherapy regimens consisting of nab-paclitaxel plus gemcitabine or FOLFIRINOX. The study intervention is given as a subcutaneous injection every four weeks. After an initial Phase 2b period where doses are evaluated, the study continues into Phase 3 with the selected ponsegromab dose or placebo. Participants may also join an optional open-label extension to receive ponsegromab for up to 12 months after the double-blind phase ends. During the study, participants will have tumor assessments approximately every 6 to 8 weeks by independent radiologists. The research team will monitor body weight changes, physical activity, quality of life measures, safety events, and survival outcomes over the course of the trial, which may last up to several years. Caregiver quality of life is also evaluated in an optional sub-study. Participants health and treatment effects will be closely followed until the studys completion in 2029.
Actively Recruiting
Researchers are evaluating the Bridges to Better Health and Wellness BRIDGES intervention, designed to reduce chronic disease disparities among Puerto Ricans living with serious mental illness SMI. This study compares the effectiveness of BRIDGES, a culturally tailored healthcare manager intervention, against standard psychiatric care. The trial aims to improve primary care use, reduce stigma, and enhance chronic disease outcomes over a 12-month period. Participants in the experimental group receive monthly sessions lasting 60 minutes each, led by graduate clinical psychology students acting as healthcare managers. These sessions focus on care coordination, patient activation, and reducing provider stigma. The control group continues with usual psychiatric care and receives an informational brochure about accessing primary care providers. The study measures outcomes at baseline, 6 months, 12 months, and also 6 and 12 months after the intervention ends. Throughout the study, participants undergo assessments including preventive primary care receipt, blood tests such as Hemoglobin A1c and lipid panels, and questionnaires on smoking dependence, physical activity, health literacy, self-stigma, provider stigma, and patient-provider relationships. These evaluations occur at multiple time points during and after the 12-month intervention. The study monitors these health and stigma measures to assess the impact of the BRIDGES program on chronic disease management and mental health care in this population.
Actively Recruiting
Researchers are studying a new medicine called PF-08634404 to see how well it works in adults with metastatic colorectal cancer, which is cancer that has spread to other parts of the body. The study compares PF-08634404 combined with approved chemotherapy to an approved medicine called Bevacizumab combined with chemotherapy. The goal is to understand if the new medicine can improve outcomes for people whose cancer has spread or returned after previous treatments. Participants are randomly assigned to one of two treatment groups. One group receives PF-08634404 with chemotherapy, and the other group receives Bevacizumab with chemotherapy. All medicines are given through intravenous IV infusions at a clinical site. Treatment is given in cycles, and participants may continue treatment as long as it is helping and side effects are manageable. After treatment ends, participants return for a final visit around 30 to 37 days later. During the study, participants have regular visits for treatment, health checks, and tests. Follow-up continues every 12 weeks through phone, in-person visits, or health record reviews to monitor health status and any new treatments. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, side effects, quality of life, and drug levels. The study is expected to last about 33 months per participant.
Actively Recruiting
Researchers are evaluating the effects of a study medicine called PF-08634404, given alone or combined with another antibody named ipilimumab, in adults with a type of liver cancer called hepatocellular carcinoma HCC that is locally advanced or has spread to other parts of the body. This study focuses on patients whose cancer cannot be removed by surgery and who have not yet received whole-body treatment for HCC. Participants will receive PF-08634404 either as a single treatment or together with ipilimumab. Both medicines will be given through intravenous IV infusions administered directly into a vein at clinical trial sites. Participants are randomly assigned to receive either the study medicine alone or in combination with the antibody, with dose levels given sequentially. During the study, participants will be monitored for safety and response to treatment, including adverse events and tumor response using standard criteria. Researchers will assess overall response rates, progression-free survival, and other health measures over approximately 24 months. Medical staff will also track blood tests, serum drug levels, and immune responses. Treatment and follow-up visits will include clinical assessments to understand the effects and side effects of these therapies.
1-10 of 15
1